Clinical Study Of Jiawei Yiqi Shengxue Prescription To Intervene Myelosuppression Caused By Chemotherapy For Non-Small Cell Lung Cancer

Objective:To investigate the clinical efficacy and safety of jiawei yiqi shengxue prescription in treating bone marrow suppression caused by chemotherapy in NSCLC patients with lung-spleen deficiency after chemotherapy,and to provide a stronger basis for the prevention and treatment of bone marrow suppression by jiawei yiqi shengxue prescription,so as to be better used in clinical practice in the future.Methods:Fifty-eight NSCLC patients admitted to the department of oncology,henan hospital of traditional Chinese medicine from December 2018 to December 2019 and meeting the experimental standards included.Patients in the contrast group received conventional GP chemotherapy.During the chemotherapy,patients in the control group were routinely given auxiliary treatment to protect liver,protect stomach and stop vomiting.In the treatment group,on the basis of the drugs used in the comparison group,the prescription for nourishing qi and generating blood was given orally.Patients in both groups were observed for 21 days(d0-d21).The main observation was the incidence of bone marrow suppression and the occurrence of different degrees of bone marrow suppression in the two groups after treatment,and the secondary observation was the dynamic changes of TCM syndrome score,quality of life and related test indexes before and after treatment in the two groups.All data were analyzed using SPSS 21.0 software,and P<0.05 indicated significant difference.Results:1.The degree and incidence of bone marrow suppression: WBC,NEUT,HGB,and PLT were compared without difference before treatment(P>0.05).After the treatmen,the decrease of WBC,NEUT and PLT in the treatment group was lower than that in the comparison group,and the degree and incidence of bone marrow suppression in the treatment group were obviously lower than that in the control group,with statistical differences(P<0.05).2.In terms of improving TCM syndrome score,there was no significant difference between the two before treatment(P>0.05);After treatment,except for low voice and shortness of breath,the integral treatment group was significantly lower than the comparison group(P<0.05).3.In terms of quality of life,there was no significant difference between the two before treatment(P>0.05).The treatment group was better than the comparison group,with obvious distinction between groups(P<0.05),After treatment.4.In terms of adverse reactions: there were no obvious adverse reaction,two groups of individual patient briefly Ⅰ-Ⅱ nausea,vomiting,not processing,can alleviate by oneself,considering associated with cisplatin.Adverse reactions in terms of liver and kidney function were rare,and even if they appeared,they were grade I.There was no difference between the two groups after rank sum test(P>0.05).Conclusion:1.Supplementing qi and generating blood can promote the recovery of bone marrow hematopoietic function in patients with lung cancer with deficiency of spleen and spleen,thereby promoting the recovery of WBC,NEUT and PLT,and weakening the degree and incidence of bone marrow suppression.2.To improve the TCM syndrome score of lung cancer patients with lung-spleen deficiency and spleen-qi deficiency,and improve the physical condition and quality of life in the process of chemotherapy,so as to facilitate the follow-up chemotherapy on time.3.Jiawei yiqi shengxue prescription is safe and reasonable for bone marrow suppression after chemotherapy in NSCLC patients,with no obvious toxic and side effects.It is worthy of clinical application and reference.